WO2025035020A3 - Diluted carfilzomib for use in treating multiple myeloma - Google Patents
Diluted carfilzomib for use in treating multiple myeloma Download PDFInfo
- Publication number
- WO2025035020A3 WO2025035020A3 PCT/US2024/041550 US2024041550W WO2025035020A3 WO 2025035020 A3 WO2025035020 A3 WO 2025035020A3 US 2024041550 W US2024041550 W US 2024041550W WO 2025035020 A3 WO2025035020 A3 WO 2025035020A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carfilzomib
- patient
- multiple myeloma
- treating multiple
- diluted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Provided herein are methods for treating a disease or condition selected from the group consisting of cancer, autoimmune disease, graft or transplant-related condition, neurodegenerative disease, fibrotic-associated condition, ischemic-related conditions, infection (viral, parasitic or prokaryotic) and diseases associated with bone loss, the method comprising administering to a patient a therapeutically effective amount of carfilzomib or a pharmaceutically acceptable salt thereof at a dose volume of 10 mL/kg or higher. Also provided herein are methods for treating multiple myeloma in a patient, comprising administering to the patient a pharmaceutical composition comprising carfilzomib or a pharmaceutically acceptable salt thereof and an aqueous carrier, wherein the carfilzomib is administered at a dose volume of 2.5 mL/kg or higher and/or at a concentration of less than 2 mg/mL.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363518343P | 2023-08-09 | 2023-08-09 | |
| US63/518,343 | 2023-08-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2025035020A2 WO2025035020A2 (en) | 2025-02-13 |
| WO2025035020A3 true WO2025035020A3 (en) | 2025-03-20 |
Family
ID=92582818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2024/041550 Pending WO2025035020A2 (en) | 2023-08-09 | 2024-08-08 | Methods of using carfilzomib |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2025035020A2 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017205392A1 (en) * | 2016-05-24 | 2017-11-30 | Amgen Inc. | Pegylated carfilzomib compounds |
| WO2018138556A1 (en) * | 2017-01-24 | 2018-08-02 | Orbicular Pharmaceutical Technologies Pvt. Ltd. | Non-aqueous carfilzomib compositions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
| ES2408216T3 (en) | 2004-12-07 | 2013-06-19 | Onyx Therapeutics, Inc. | Composition for proteasome inhibition |
| MX2010003732A (en) | 2007-10-04 | 2010-08-09 | Onyx Therapeutics Inc | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides. |
| PE20120059A1 (en) | 2008-10-21 | 2012-02-27 | Onyx Therapeutics Inc | PHARMACEUTICAL COMBINATIONS WITH PEPTIDIC EPOXYCETONES |
| BR112012028726B1 (en) | 2012-05-08 | 2021-07-13 | Onyx Therapeutics, Inc. | METHOD FOR PREPARING A LOW CHLORIDE PHARMACEUTICAL COMPOSITION |
| US9309283B2 (en) | 2012-07-09 | 2016-04-12 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
| US10022326B2 (en) | 2012-07-18 | 2018-07-17 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
| DE102013104003B3 (en) | 2013-04-19 | 2014-03-13 | Glatt Systemtechnik Gmbh | Device for introducing a defined amount of a second powder into a process container |
-
2024
- 2024-08-08 WO PCT/US2024/041550 patent/WO2025035020A2/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017205392A1 (en) * | 2016-05-24 | 2017-11-30 | Amgen Inc. | Pegylated carfilzomib compounds |
| WO2018138556A1 (en) * | 2017-01-24 | 2018-08-02 | Orbicular Pharmaceutical Technologies Pvt. Ltd. | Non-aqueous carfilzomib compositions |
Non-Patent Citations (1)
| Title |
|---|
| BRINGHEN SARA ET AL: "Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies", HAEMATOLOGICA, vol. 104, no. 8, 1 August 2019 (2019-08-01), pages 1640 - 1647, XP093222355, ISSN: 0390-6078, Retrieved from the Internet <URL:https://pmc.ncbi.nlm.nih.gov/articles/PMC6669142/pdf/1041640.pdf> DOI: 10.3324/haematol.2018.208272 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025035020A2 (en) | 2025-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH04364133A (en) | Use of anti-tnf antibody as medicine for treatment of ischemia and its concomitant symptom | |
| AU664354B2 (en) | Treatment of organ transplantation rejection | |
| RU2008142899A (en) | DALBAVANCIN COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS | |
| US20100266590A1 (en) | Combination therapy | |
| US20200061104A1 (en) | Silicate containing compositions and methods of treatment | |
| Brouwers | Advanced and controlled drug delivery systems in clinical disease management | |
| EP4520394A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| WO1991002529A2 (en) | Product and method for killing abnormal vertebrate cells | |
| WO2025035020A3 (en) | Diluted carfilzomib for use in treating multiple myeloma | |
| JP2000507234A (en) | Intranasal administration of treatment for delayed onset vomiting | |
| CN114939122B (en) | Combined antitumor pharmaceutical composition derived from natural plants | |
| WO2021221537A1 (en) | Sars-cov-2 antiviral drug antiprovir | |
| Swan et al. | Mycotic endophthalmitis caused by Penicillium sp. after parenteral drug abuse | |
| Lefrère et al. | Successful peripheral blood stem cell harvesting with granulocyte colony-stimulating factor alone after previous mobilization failure | |
| CN109966290A (en) | Application of CID1067700 in the preparation of medicine for preventing and/or treating cerebrovascular disease and its pharmaceutical composition | |
| DE4329857C2 (en) | Connection to strengthen the immune system and immune reactions | |
| CA3254293A1 (en) | Novel retinoic acid compound, pharmaceutical composition including thereof and use thereof | |
| US4680311A (en) | Method for the treatment of systemic mycosis | |
| US6455555B1 (en) | Anti-HIV infection agents and method for treating HIV infection | |
| RU2282437C1 (en) | Agent for treatment of joint disease | |
| RU2180532C2 (en) | Method for treating the cases of papillomatosis | |
| US7846901B2 (en) | Method for inhibiting or treating intestinal damage caused by radiotherapy or chemotherapy comprising administering substance-P | |
| CN117243946A (en) | Application of daphnetin and composition containing daphnetin in preparation of myocarditis treatment drugs | |
| CZ128095A3 (en) | Antimalarial medicament | |
| RU2217137C2 (en) | Method for limitation of complications and adverse symptoms in treatment of tuberculosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 24762493 Country of ref document: EP Kind code of ref document: A2 |